Stock BCLI BRAINSTORM CELL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Brainstorm Cell Therapeutics Inc.

Equities

BCLI

US10501E2019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
0.5169 USD -3.80% Intraday chart for Brainstorm Cell Therapeutics Inc. -8.84% +89.34%
May. 20 BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit from Longer-Term Treatment with NurOwn CI
Apr. 17 Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Maxim Downgrades Brainstorm Cell Therapeutics to Hold From Buy
MT
Fed rates at 7%: Is it on the cards?
Our Logo
Maxim Group Adjusts Price Target on Brainstorm Cell Therapeutics to $10 From $5, Maintains Buy Rating
MT
BRAINSTORM CELL THERAPEUTICS : Maxim Group Upgrades Brainstorm Cell Therapeutics to Buy From Hold
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCLI Stock
  4. News Brainstorm Cell Therapeutics Inc.
  5. Analyst Reco.